United Kingdom· GB-APID-39815111000001103
Harvoni 45mg/200mg tablets
A sofosbuvir and ledipasvir product containing ledipasvir + sofosbuvir, registered in United Kingdom by Gilead Sciences Ltd. The same ATC class is registered in 13 of our 19 countries.
Checked against NHS dm+d (United Kingdom) on
Informational only — not a medical device.
Where it is registered
Sofosbuvir and ledipasvir is registered in 13 of 19 countries.
Countries holding a registration under ATC J05AP51 (sofosbuvir and ledipasvir), each read from that country’s own register.
- This record: United Kingdom, from NHS dm+d (United Kingdom)
- 8 of them publish a price we can compare per daily dose
Sofosbuvir and ledipasvir · ATC J05AP51
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- United Kingdom
- United Statesprice
The record
At a glance
NHS dm+d (United Kingdom)- Active substance
- Ledipasvir + Sofosbuvir
- Manufacturer
- Gilead Sciences Ltd
- Country
- United Kingdom (GB)
- ATC code
- J05AP51
- ATC class
- Sofosbuvir and ledipasvir
- Reimbursed
- Not published by this register
- Source register
- NHS dm+d (United Kingdom)
- Last checked
- September 13, 2026
Packs & prices · 2
- gtin05391507146052
- gtin05391507145994
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Sofosbuvir and ledipasvir in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesHarvoniGilead Sciences, Inc
- CzechiaHARVONIGilead Sciences Ireland UC, Carrigtohill
- IrelandHarvoni 33.75 mg/150 mg Coated granulesGilead Sciences Ireland UC
- FinlandHarvoniGilead Sciences Ireland UC
- IcelandHarvoniGilead Sciences Ireland UC*
- NetherlandsHarvoni 33,75 mg/150 mg, granulaatGilead Sciences Ireland UC
- PolandHarvoniGilead Sciences Ireland UC
- SwedenHarvoni 33,75 mg/150 mg Dragerat granulat i dospåseGilead Sciences Ireland UC
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Harvoni
- Liechtenstein · Harvoni
- Norway · Harvoni
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b9baf2d3-c67c-42ac-b2b9-67bad337dc7d GET /v1/drugs/b9baf2d3-c67c-42ac-b2b9-67bad337dc7d?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"apid": "39815111000001103",
"desc": "Harvoni 45mg/200mg tablets (Gilead Sciences Ltd)",
"form": "Oral tablet",
"vpid": "39819211000001107",
"source": "dmd",
"vtm_id": "776492003",
"strength": "200 mg",
"substance": "Ledipasvir + Sofosbuvir",
"ingredient": "Sofosbuvir",
"supplier_code": "2572301000001107"
}See everything about sofosbuvir and ledipasvir.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.